http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update
-
DURECT Corp (DRRX) Reports Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
-
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality
-
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
-
DURECT Corporation Announces Presentations in Upcoming Investor Conferences
-
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
-
DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update
-
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
-
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8
-
DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis
-
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
-
DURECT Corp (DRRX) Announces Peer-Reviewed Publication of Additional Data from Previously Completed Phase 2a Study of Larsucosterol
-
DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis
-
DURECT Corp (DRRX) Appoints Gail Maderis as Board Chair
-
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board
-
DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference
-
DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update
-
DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7
-
DURECT Corp (DRRX) Announces 1-for-10 Reverse Stock Split
-
DURECT Announces 1-for-10 Reverse Stock Split
-
DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
-
DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2
-
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial
-
DURECT Corp (DRRX), Innocoll Announce U.S. launch of POSIMIR
-
Innocoll and DURECT Announce U.S. launch of POSIMIR®
-
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
-
DURECT Corporation Reports Second Quarter 2022 Financial Results and Update of Programs
-
DURECT Corporation to Announce Second Quarter 2022 Financial Results and Provide Business Update on August 4
-
DURECT Corp (DRRX) Appoints Timothy M. Papp as Chief Financial Officer
-
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer
-
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
-
DURECT Corporation Reports First Quarter 2022 Financial Results and Update of Programs
-
DURECT Corporation to Announce First Quarter 2022 Financial Results and Provide Business Update on May 4
-
DURECT Corporation To Present at the 2022 Cantor Fitzgerald Virtual Rare Orphan Disease Summit
-
DURECT Corporation Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference
-
DURECT Corporation Reports Fourth Quarter and Full Year 2021 Financial Results and Update of Programs
-
DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis
-
DURECT Corporation to Announce Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on March 7
-
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
-
DURECT Corp (DRRX) and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR
-
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
-
DURECT Corporation Expands Board of Directors with Appointment of Biopharmaceutical Industry Finance Veteran Peter Garcia
-
DURECT Corporation to Participate in Alcoholic Liver Disease Workshop Today at the 5th Annual NASH Summit
-
Data Presentation Today at The Liver Meeting® 2021 Shows Increasing Hospital Admissions for Alcohol-Associated Hepatitis (AH) in the U.S.
-
DURECT Corporation Doses First ex-U.S. Patient in Phase 2b AHFIRM Study of Larsucosterol (DUR-928) in Severe Alcohol-Associated Hepatitis
-
DURECT Corporation Announces Poster Presentation on the Prevalence of Hospitalized Alcohol-Associated Hepatitis (AH) Patients in the U.S. to be Presented at The Liver Meeting® 2021
-
DURECT Corporation Reports Third Quarter 2021 Financial Results and Update of Programs
-
DURECT Corporation to Announce Third Quarter 2021 Financial Results and Provide Business Update on November 2
-
DURECT Corporation Fireside Chat at the H.C. Wainwright 5th Annual NASH Investor Conference
-
DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021
